Literature DB >> 21377583

Radiofrequency ablation of neuroendocrine hepatic metastasis.

T Clark Gamblin1, Kathleen Christians, Sam G Pappas.   

Abstract

Neuroendocrine cancer commonly metastasizes to the liver and often presents as unresectable disease. Liver resection or debulking most of the tumor provides a survival advantage for patients. Whether used alone or in combination with resection, radiofrequency ablation provides a unique tool to destroy metastases to the liver and spare hepatic parenchyma. Although randomized trials are lacking, retrospective series provide promising data to consider radiofrequency ablation in the management of hepatic neuroendocrine metastases. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21377583     DOI: 10.1016/j.soc.2010.11.002

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  12 in total

Review 1.  The Landmark Series: Neuroendocrine Tumor Liver Metastases.

Authors:  Alexandra Gangi; James R Howe
Journal:  Ann Surg Oncol       Date:  2020-07-06       Impact factor: 5.344

Review 2.  Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with review of the literature.

Authors:  Kai Yang; Ying-Sheng Cheng; Ji-Jin Yang; Xu Jiang; Ji-Xiang Guo
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 3.  Radiofrequency ablation of liver tumors.

Authors:  Shaunagh McDermott; Debra A Gervais
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

4.  Recurrence after microwave ablation of liver malignancies: a single institution experience.

Authors:  Ryan T Groeschl; Ray K Wong; Edward J Quebbeman; Susan Tsai; Kiran K Turaga; Sam G Pappas; Kathleen K Christians; Eric J Hohenwalter; Sean M Tutton; William S Rilling; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2012-10-11       Impact factor: 3.647

5.  Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection.

Authors:  Timucin Taner; Thomas D Atwell; Lizhi Zhang; Trynda N Oberg; William S Harmsen; Seth W Slettedahl; Michael L Kendrick; David M Nagorney; Florencia G Que
Journal:  HPB (Oxford)       Date:  2012-07-26       Impact factor: 3.647

6.  Primary hepatic neuroendocrine tumor: A case report.

Authors:  Asahiro Morishita; Hirohito Yoneyama; Takako Nomura; Teppei Sakamoto; Koji Fujita; Joji Tani; Hisaaki Miyoshi; Reiji Haba; Tsutomu Masaki
Journal:  Mol Clin Oncol       Date:  2016-03-17

Review 7.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

8.  Metastatic neuroendocrine tumor with metastases to the right liver in a patient with absent left portal vein.

Authors:  Reid C Mahoney; Kyrillos Awad; Gregorio Maldini
Journal:  J Surg Case Rep       Date:  2021-05-27

Review 9.  Current and emerging therapies for PNETs in patients with or without MEN1.

Authors:  Morten Frost; Kate E Lines; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-02-16       Impact factor: 43.330

Review 10.  Surgical Management of Neuroendocrine Tumor Liver Metastases.

Authors:  Catherine G Tran; Scott K Sherman; Chandrikha Chandrasekharan; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2020-10-20       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.